Dr. Chawla’s Presentations at the 7th International Conference on Drug Discovery Therapies, Dubai, February 17, 2016

More Presentations:


Interviews from the National American Association for Cancer Research Conference (AACR 2024)

Nadia Omelchenko, MD, Sarcoma Oncology Research Center, Santa Monica, CA, summarizes the current landscape for predictive biomarkers for checkpoint inhibitors (CI) in sarcoma. Expression of PD-(L)1 and CTLA-4 has been explored as biomarkers to predict response to CI treatment in various cancers, though there is no trial data yet for advanced sarcomas. Sarcoma cells are greatly immunogenic, but the Phase II SAINT study (NCT03138161) shows promising progress free survival and overall survival through the use of trabectedin, ipilimumab and nivolumab.


This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP)

Nadia Omelchenko, MD, Sarcoma Oncology Research Center, Santa Monica, CA, discusses trials combining immune checkpoint inhibitors (ICI) with chemotherapy in patients with advanced soft tissue sarcomas (STC). The Phase I/II SAINT trial (NCT03138161) combines ipilimumab and nivolumab with trabectedin, demonstrating safe and effective results as a first line treatment. A new study, LINNOVATE (NCT05876715), with a similar protocol, is testing ipilimumab and nivolumab with lurbinectedin, an analog of trabectedin with shorter infusion time.


This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP)


Ariad Pharmaceuticals News Release

The Sarcoma Oncology Center is pleased to see preliminary results from the Ariad/Merck clinical trial for advanced sarcoma. The SUCCEED trial is studying a targeted investigational drug, ridaforolimus, as maintenance therapy for patients who have responded to their chemotherapy. 711 patients from all over the world participated in the trial. In the their press release, Ariad said the results so far show treatment with ridaforolimus reduced the risk of disease progression by 28% compared to placebo treatment, and increased progression free survival by a statistically significant amount of time.

Of 155 global sites that participated in the study, the Sarcoma Oncology Center had the highest patient participation, with 60 of our patients with advanced sarcoma receiving treatment under this important clinical trial. As the highest enrolling investigator, Dr. Chawla will present the study results at the upcoming American Society of Clinical Oncology annual meeting June 4-8 in Chicago IL. Dr. Chawla says, “We are pleased by the strong positive trend of the data, and we anticipate seeing the response data improve a bit further as patients continue to receive ridaforolimus. The greatest credit belongs to our patients, who have kept the commitment to try these new research medicines and help us to develop the new treatments for sarcoma. We are most grateful for every patient who takes part in clinical research with us. You are the most important members of the research team.”

Click here to view full news release.

Back to top


Chawla’s ASCO Meeting Presentations

American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

1. A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.

2. Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.

3. Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.

4. TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.

5. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

6. Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.

7. A phase 1b investigation of safety/efficacy of nivolumab and ABI-009 (nab-rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing sarcoma.

8. Cancer immunotherapy using trabectedin and nivolumab in advanced soft tissue sarcoma: A retrospective analysis

9. Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy.

10. Genomic and proteomic analysis of patient tumors for molecular target selection.

11. Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

12. Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

Back to top


American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

1. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas.

2. Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.

3. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.

4. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.

5. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).

Back to top


American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

1. Phase 2 study of aldoxorubicin in relapsed glioblastoma.

2. Trabectedin for advanced soft-tissue sarcoma: A single-center experience of over 10 years.

3. A phase 1/2 study of continuous infusion ifosphamide/mesna + aldoxorubicin in sarcoma patients.

4. Long-term treatment of giant cell tumors of bone (GCTB) with denosumab: a two institutions 8-year experience.

5. Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors.

6. Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).

7. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).

Back to top


American Society of Clinical Oncology (ASCO) 2015 Annual Meeting

1. Study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.

2. Longer term cardiac safety of aldoxorubicin.

3. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).

4. Molecularly-guided therapeutic options beyond tyrosine kinase inhibitors (TKIs) for gastrointestinal stromal tumors (GIST).

5. Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.

6. Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.

7. Sustained response of complex giant cell tumors with denosumab: Single center 8-year experience.

Back to top


American Society of Clinical Oncology (ASCO) 2014 Annual Meeting

1. Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas.

2. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).

3. Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.

4. Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.

5. 14-day continuous infusion ifosfamide in advanced refractory sarcomas.

Dr. Chawla’s 2014 ASCO Meeting Presentation

As the principal investigator, Dr. Sant Chawla was asked to present the results of the Phase 2b Clinical Trial comparing Aldoxrubicin to Doxorubicin in patients with advanced soft tissue sarcomas at the ASCO 2014 Annual Meeting. See his presentation below:

Click here to download more information: CytRx Aldoxorubicin Clinical Trial Phase 2B Information & Results Presented at ASCO

Back to top


American Society of Clinical Oncology (ASCO) 2013 Annual Meeting

1. Phase 1b study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma.

2. A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies.

3. Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

4. A phase II trial of novel anthracycline amrubicin in advanced soft tissue sarcoma

5. Phase Ib trial of combining aldoxorubicin plus doxorubicin.

6. A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.

Back to top


American Society of Clinical Oncology (ASCO) 2012 Annual Meeting

1. Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.

2. Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity.

3. Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue sarcoma.

4. Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo.

5. Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).

Back to top


American Society of Clinical Oncology (ASCO) 2011 Annual Meeting

This years meeting was very exciting for sarcoma patients and doctors!! The biggest presentation this year was a discussion on the length of treatment for gastro-intestinal stromal tumors. We are also very proud to announce that several of the research studies that our patients contributed to have made a large impact on how we will treat sarcoma in the future. It appears that 4 new drugs will be vying for FDA approval based on the results from this year’s conference.

The SUCCEED trial demonstrated that placing a patient on a maintenance therapy of Ridafarolimus, an oral pill, can help keep the cancer under control with minimal side effects. This was discussed by Sant Chawla and other experts from Dana Farber and MD Anderson at the oral presentations.

Another breakthrough was the PALLETE study which examined the angiogenesis inhibitor Pazopanib. This study demonstrated that by taking this medication orally you can help control metastatic sarcomas. Our patients contributed more than any other site in the United States!

The combination of a new medication named Threshold appears to be very promising in combination with adriamycin. This medication has very few side effects and it is highly active in patients with soft tissue sarcomas. We are looking forward to the phase 3 study that will be opening shortly.

Finally there is a new medicine for patients with giant cell tumor of the bone. After years of ineffective therapy for unresectable tumors we now have a new medicine that can control this disease in 90% of patients!! Our center and generous patients were vital in having this medication studied. This will be approved shortly and will improve the lives of many people.

Our patients have also been instrumental in the development of a 3rd generation anthracycline named Amrubicin. We will continue to study this medication and hope that will prove to be a new and highly effective medication for our patients.

Download the presentations: Amrubicin ASCO 2012    Denosumab ASCO 2011    SUCCEED ASCO 2011

Back to top


Dr. Chawla’s CTOS Meeting Presentations

Connective Tissue Oncology (CTOS) 2018 Annual Conference in Rome, Italy

1. AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA
Michael Heinrich1 ; Margaret von Mehren2 ; Robin L. Jones3 ; Sebastian Bauer4 ; Yoon-Koo Kang5 ; Patrick Schöffski6 ; Ferry Eskens7 ; Cesar Serrano8 ; Philippe Cassier9 ; Olivier Mir10; William D. Tap11; Piotr Rutkowski12; Jonathan Trent13; Shreyaskumar Patel14; Sant P. Chawla15; Teresa Zhou16; Tamieka Lauz16; Oleg Schmidt-Kittler16; Khalid K. Mamlouk16; Beni B. Wolf16; Suzanne George17 1 OHSU Knight Cancer Institute, Portland, OR, USA; 2 Fox Chase Cancer Centre, Philadelphia, PA, USA; 3 Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; 4 University of Duisburg-Essen, Essen, Germany; 5 Asan Medical Centre, Seoul, Korea (the Republic of); 6 University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; 7 Erasmus MC Cancer Institute, Rotterdam, Netherlands; 8 Vall d’ Hebron Institute of Oncology , Barcelona, Spain; 9 Centre Léon Bérard, Lyon, France; 10Institut Gustave Roussy; Edouard Vaillant Villejuif, Villejuif, France; 11Memorial Sloan Kettering Cancer Centre, New York, NY, USA; 12Maria Sklodowska-Curie Institute – Oncology Center, Warszawa, Poland; 13Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; 14MD Anderson Cancer Center, Houston, TX, USA; 15Sarcoma Oncology Centre , Santa Monica, CA, USA; 16Blueprint Medicines Corporation, Cambridge , MA, USA; 17Dana Farber Cancer Institute, Boston, MA, USA

2. RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla1 ; Seth Pollack2 ; Matthew Block7 ; Mihaela Druta3 ; Khanh Do4 ; John C. Morris5 ; Joseph W. Kim6 ; Chet Bohac8 ; Hailing Lu9 ; Sacha Gnjatic10; Robin L. Jones11; P. Hwu12; Neeta Somaiah13 1 Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2 Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3 Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4 Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5 Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6 Medical Oncology, Yale University, New Haven, CT, USA; 7 Medical Oncology, Mayo clinic, Rochester, MN, USA; 8 Clinical Development, Immune Design, South San Francisco, CA, USA; 9 Science, Immune Design, Seattle, WA, USA; 10Immunology, Mt. Sinai, New York City, NY, USA; 11Medical Oncology, Royal Marsden, London, United Kingdom; 12Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 13Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

3. IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla1 ; Seth Pollack2 ; Matthew Block11; Mihaela Druta3 ; Khanh Do4 ; John C. Morris5 ; Joseph W. Kim6 ; Chet Bohac7 ; Hailing Lu7 ; Sacha Gnjatic8 ; R. L. Jones9 ; P. Hwu10; Neeta Somaiah10 1 Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2 Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3 Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4 Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5 Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6 Medical Oncology, Yale University, New Haven, CT, USA; 7 Science, Immune Design, Seattle, WA, USA; 8 Immunology, Mt. Sinai, New York City, NY, USA; 9 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 10Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 11Medical Oncology, Mayo Clinic, Rochester, MN, USA

4. SARC024: REGORAFENIB IN PATIENTS WITH REFRACTORY OSTEOSARCOMA
Lara E. Davis1 ; Christopher Ryan1 ; John Crowley2 ; Kristen Ganjoo3 ; Elizabeth Loggers4 ; Sant P. Chawla5 ; Mark Agulnik6 ; Michael B. Livingston7 ; Damon Reed8 ; Vicki Keedy9 ; Daniel A. Rushing10; Scott Okuno11; Denise Reinke12; Richard F. Riedel13; Steven Attia14; Leo Mascarenhas15; Robert Maki16 1 Oregon Health and Science University, Portland, OR, USA; 2 Cancer Research and Biostatistics, Seattle, WA, USA; 3 Stanford Cancer Institute, Stanford, CA, USA; 4 Seattle Cancer Care Alliance, Seattle, WA, USA; 5 Sarcoma Oncology Research Center, Santa Monica, CA, USA; 6 Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 7 Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; 8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 9 Vanderbilt University Medical Center, Nashville, TN, USA; 10Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; 11Mayo Clinic, Rochester, MN, USA; 12SARC, Ann Arbor, MI, USA; 13Duke University Medical Center, Durham, NC, USA; 14Mayo Clinic, Jacksonville, FL, USA; 15Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA; 16Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY, USA

5. DETECTION OF ENDOGLIN-EXPRESSING CTCS IN PATIENTS ENROLLED IN AN ADAPTIVE ENRICHMENT PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)
Ravi Vinod2 ; Andrew Brohl3 ; Robin Jones4 ; Sant P. Chawla5 ; Kristen Ganjoo14; Steven Attia10; Atrayee Basu-Mallick9 ; Darren Davis6 ; Mario Cervantes6 ; Wen Liu6 ; Lilian Liu1 ; Charles Theuer1 ; Steven Robinson11; Nicolas Penel12; Silvia Stacchiotti13; William D. Tap7 ; Robert Maki8 1 TRACON Pharma, San Diego, CA, USA; 2 University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; 3 Moffitt Cancer Center, Tampa, FL, USA; 4 Royal Marsden/ Institute of Cancer Research, London, United Kingdom; 5 Sarcoma Oncology Center, Santa Monica, CA, USA; 6 ApoCell, Houston, TX, USA; 7 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 8 Northwell Health, Lake Success, NY, USA; 9 Thomas Jefferson University, Philadelphia, PA, USA; 10Mayo Clinic, Jacksonville, FL, USA; 11Mayo Clinic, Rochester, MN, USA; 12Centre Oscar Lambret, Lille, France; 13Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 14Stanford University, Stanford, CA, USA

6. RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla1 ; Seth Pollack2 ; Matthew Block7 ; Mihaela Druta3 ; Khanh Do4 ; John C. Morris5 ; Joseph W. Kim6 ; Chet Bohac8 ; Hailing Lu9 ; Sacha Gnjatic10; Robin L. Jones11; P. Hwu12; Neeta Somaiah13 1 Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2 Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3 Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4 Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5 Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6 Medical Oncology, Yale University, New Haven, CT, USA; 7 Medical Oncology, Mayo clinic, Rochester, MN, USA; 8 Clinical Development, Immune Design, South San Francisco, CA, USA; 9 Science, Immune Design, Seattle, WA, USA; 10Immunology, Mt. Sinai, New York City, NY, USA; 11Medical Oncology, Royal Marsden, London, United Kingdom; 12Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 13Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

7. IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla1 ; Seth Pollack2 ; Matthew Block11; Mihaela Druta3 ; Khanh Do4 ; John C. Morris5 ; Joseph W. Kim6 ; Chet Bohac7 ; Hailing Lu7 ; Sacha Gnjatic8 ; R. L. Jones9 ; P. Hwu10; Neeta Somaiah10 1 Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2 Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3 Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4 Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5 Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6 Medical Oncology, Yale University, New Haven, CT, USA; 7 Science, Immune Design, Seattle, WA, USA; 8 Immunology, Mt. Sinai, New York City, NY, USA; 9 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 10Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 11Medical Oncology, Mayo clinic, Rochester, MN, USA

8. THE SAINT: INITIAL RESULTS OF A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB AND TRABECTEDIN AS FIRST LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA
Erlinda M. Gordon1 ; Victoria M. Chua-Alcala1 ; Katherine M. Kim1 ; S. Sreenath M. Andrali1 ; Doris M. Quon1 ; Steven M. Wong1 ; William W. Tseng2 ; Seth Pollack3 ; Amornchit M. Srikureja1 ; Noah Federman4 ; Sant P. Chawla1 1 Sarcoma Oncology Center, Santa Monica, CA, USA; 2 Surgery, USC Keck School of Medicine, Los Angeles, CA, USA; 3 Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 4 Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA

9. RELAX: AN IMMERSION VIRTUAL REALITY RELAXATION INTERVENTION FOR QUALITY OF LIFE IMPROVEMENT IN CANCER PATIENTS
Erlinda M. Gordon1 ; Bryan M. Li2 ; Seiya M. Liu2 ; Sant P. Chawla1 ; Seiji M. Liu2 ; Stephen M. Liu2 1 Sarcoma Oncology Center, Santa Monica, CA, USA; 2 IFGCURE, Santa Monica, CA, USA

Back to top


Connective Tissue Oncology (CTOS) 2017 Annual Conference in Maui, Hawaii

1. A PHASE 2 STUDY OF CMB305 AND ATEZOLIZUMAB IN NY-ESO-1+ SOFT TISSUE SARCOMA: INTERIM ANALYSIS OF IMMUNOGENICITY, TUMOR CONTROL AND SURVIVAL

S. Chawla, Medical Oncology, Sarcoma Center, Santa Monica, California, USA; B.A. Van Tine, Me, Washington University, St Louis, Missouri, USA; S.M. Pollack, Med, Fred Hutchinson Cancer Center, Seattle, Washington, USA; K. Ganjoo, Medical Oncology, Stanford , Palo Alto, California, USA; A. Elias, Medical Oncology, University of Colorado , Denver, Colorado, USA; R. Riedel, Medical Oncology, Duke University, Durham, North Carolina, USA; S. Attia, Medical Oncology, Mayo , Jacksonville, Florida, USA; E. Choy, Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; S. Okuno, Medical Oncology, Mayo, Rochester, Minnesota, USA; M. Agulnik, Medical Oncology, Northwestern, Chicago, Illinois, USA; M. von Mehren, Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; M. Livingston, Medical Oncology, Carolinas Healthcare System, Charlotte, North Carolina, USA; V. Keedy, Medical Oncology, Vanderbilt, Nashville, Tennessee, USA; C. Verschraegen, Medical Oncology, Ohio State University Medical Center, Columbus, Ohio, USA; R. Maki, Medical Oncology, Northwell Health System, New Hyde Park, New York, USA

2. CANCER IMMUNOTHERAPY USING TRABECTEDIN AND NIVOLUMAB IN ADVANCED SOFT TISSUE SARCOMA: A RETROSPECTIVE ANALYSIS

Sant Chawla1; Kamalesh Sankhala1; Stumpf Nathan1; Seth Kim1; Susan Arasheben1; Leong Bryan1; Grace Kang1; William W. Tseng, MD2; Erlinda M. Gordon, MD1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Surgery, USC Keck School of Medicine, Los Angeles, CA, USA

3. PRELIMINARY EVIDENCE OF CLINICAL RESPONSE TO ENTRECTINIB IN THREE SARCOMA PATIENTS

P. Multani, E. Chow Manavel, Z. Hornby, S.J. Potts, P.J. Foley, Ignyta, Inc., San Diego, California, USA; S. Chawla, V.S. Chua, K. Kim, L. Bryan, E.M. Gordon, D. Quon, K. Sankhala, Sarcoma Oncology Center, Santa Monica, California, USA

4. ASSOCIATION OF NY-ESO-1 EXPRESSION WITH BASELINE IMMUNITY AND CLINICAL OUTCOMES IN SOFT TISSUE SARCOMA (STS) PATIENTS (PTS) TREATED WITH LV305 OR CMB305

S.M. Pollack, Medical Oncology, Fred Hutchinson Cancer Center, Seattle, Washington, USA; S. Chawla, Medical Oncology, Sarcoma Center, Santa Monica, California, USA; M. Druta, Moffitt Cancer Center, Tampa, Florida, USA; J. Morris, Medical Oncology, University of Cincinnati, Cincinnati, Ohio, USA; K. Do, Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; J. Kim, Medical Oncology, Yale, New Haven, Connecticut, USA; N. Somaiah, Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA; M. Block, Medical Oncology, Mayo, Rochester, Minnesota, USA; C. Bohac, M. Chen, Biostatistics, Immune Design, South San Francisco, California, USA; H. Lu, Pre-Clinical, Science, Immune Design, Seattle, California, USA

5. SEQUENCE-SPECIFIC ANTIBODIES FOR IDENTIFICATION, CAPTURE AND CHARACTERIZATION OF CIRCULATING SARCOMA CELLS AND CELLS UNDERGOING EPITHELIAL TO MESENCHYMAL TRANSITION

E.M. Gordon, S. Chawla, Sarcoma Oncology Center, Santa Monica, California, USA; P. Pagano, W. Strauss, P. Dempsey, P. Song, R. Reed, Cynvenio Biosystems, Westlake Village, California, USA; F. Hall, Counterpoint Biomedica LLC, Santa Monica, California, USA

6. PHASE II, MULTI-CENTER, RANDOMIZED TRIAL OF GEMCITABINE WITH PAZOPANIB OR GEMCITABINE WITH DOCETAXEL IN PREVIOUSLY TREATED SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA

N. Somaiah, A.P. Conley, Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA; B.A. Van Tine, Washington University, St Louis, Missouri, USA; M. Milhem, University of Iowa Hospitals, Iowa City, Iowa, USA; E. Garrett-Mayer, J. Kim, D. Reuben, MUSC , Charleston, South Carolina, USA; S. Schuetze, University of Michigan, Ann Arbor, Michigan, USA; C.F. Meyer, John Hopkins, Baltimore, Maryland, USA; A. Elias, University of Colorado, Denver, Colorado, USA; W. Read, Emory, Atlanta, Georgia, USA; S. Chawla, Sarcoma Oncolgy Center, Santa Monica, California, USA; A. Kraft, University of Arizona Cancer Center, Tucson, Arizona, USA

7. SAFETY AND EFFICACY OF DENOSUMAB IN PATIENTS WITH GIANT CELL TUMOR OF BONE: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY

A. Feng, D. Jandial, Amgen Inc., Thousand Oaks, California, USA; S. Ferrari, Istituto Ortopedico Rizzoli, Bologna, ITALY; J. Blay, Centre Léon Bérard Cancer Center, Lyon, FRANCE; P. Reichardt, HELIOS Klinikum Berlin-Buch, Berlin-Buch, GERMANY; A. Lecesne, Institut Gustave Roussy, Villejuif, FRANCE; P. Rutkowski, Maria Sklodowska-Curie InstituteOncology Center, Warsaw, POLAND; R. Henshaw, Georgetown University, Washington Cancer Institute at Medstar Washington Hospital Center, Washington, District of Columbia, USA; R.J. Grimer, Royal Orthopaedic Hospital, NHS Foundation, Birmingham, UNITED KINGDOM; S. Chawla, Sarcoma Oncology Center, Santa Monica, California, USA

Back to top


Connective Tissue Oncology (CTOS) 2016 Annual Conference in Lisbon, Portugal

1. RESPONSE TO CHECKPOINT INHIBITION IN A PEDIATRIC PATIENT WITH METASTATIC REFRACTORY CHORDOMA

Steven J. Jonas, MD, PhD1; Caroline J. Gross1; Mitchell Kamrava2; Arun S. Singh3; Jeffrey Goldstein4; Nicholas Bernthal5; Frederick C. Eilber6; Erlinda M. Gordon7; Sant P. Chawla7; Noah Federman1 1Pediatric Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA, USA; 2Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; 3Medicine, Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA, USA; 4Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA; 5Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, CA, USA; 6Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA; 7Sarcoma Oncology, Cancer Center of Southern California, Santa Monica, CA, USA

2. IMMUNOHISTOCHEMISTRY SCREENING TO INCREASE THE EFFICIENCY OF NEXT GENERATION SEQUENCING FOR DETECTION OF RARE NTRK, ROS1, AND ALK GENE FUSIONS IN SARCOMA PATIENTS

K. Kumar Sankhala2; Steven J. Potts, PhD1; Jason Christiansen1; Patrick Foley1; Katherine Kim2; Suzan Arasheben2; Bryan Leong2; Shayan Senaati2; Pratik Multani1; Zach Hornby1; Danielle Murphy1; Jennifer Lamoureux1; Sant P. Chawla2 1Ignyta Pharmaceuticals, San Diego, CA, USA; 2Sarcoma Oncology Center, Santa Monica, CA, USA

3. CONTRAST-ENHANCED ULTRASOUND (CEUS) IN DIAGNOSIS, EVALUATION, AND MANAGEMENT OF SOFT TISSUE SARCOMA (STS)

Mittul Gulati, MD1; William W. Tseng2; James Hu3; Sant P. Chawla3; Darryl Hwang1; Bhushan Desai1; Vinay Duddalwar1 1Radiology, Keck USC School of Medicine, La Canada Flintridge, CA, USA; 2Surgery, Keck USC School of Medicine, Los Angeles, CA, USA; 3Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA

4. A PHASE 1/2 STUDY OF ALDOXORUBICIN AND 14 DAYS CONTINUOUS INFUSION OF IFOSFAMIDE/MESNA IN METASTATIC OR LOCALLY ADVANCED SARCOMAS

Sant P. Chawla, MD1; K. Kumar Sankhala1; Shanta Chawla2; Victoria Chua1; Erlinda M. Gordon1; Neal Chawla1; Kelli Sung2; Doris Quon1; Katherine Kim1; Lita Fernandez1; Bryan Leong1; Scott Wieland2; Daniel Levitt2 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2CytRx Corporation, Los Angeles, CA, USA

5. RANDOMIZED PHASE 3, MULTICENTER, OPEN-LABEL STUDY COMPARING EVOFOSFAMIDE (EVO) IN COMBINATION WITH DOXORUBICIN (D) VS. D ALONE IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (STS); STUDY TH-CR-406/SARC021

William Tap1; Zsuzsanna Papai2; Brian Van Tine3; Steven Attia4; Kristen Ganjoo5; Robin Jones6; Scott Schuetze7; Damon Reed8; Sant P. Chawla9; Richard Riedel11; Antoine Italiano14; Peter Hohenberger10; Thierry Alcindor15; Stewart Kroll12; Patrick Schöffski13 1Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Allami Egeszsegugyi Kozpont, Budapest, Hungary; 3Washington University St. Louis, St. Louis, MO, USA; 4Mayo Clinic Florida, Jacksonville, FL, USA; 5Stanford University, Stanford, CA, USA; 6Royal Marsden, London, United Kingdom; 7University of Michigan, Ann Arbor, MI, USA; 8Moffitt Cancer Center, Tampa, FL, USA; 9Sarcoma Oncology, Santa Monica, CA, USA; 10Universitatsklinikum Mannheim, Mannheim, Germany; 11Duke University, Durham, NC, USA; 12Threshold Pharmaceuticals, South San Francisco, CA, USA; 13Universitair Ziekenhuis Leuven – Gathuisberg, Leuven, Belgium; 14Institut Bergonie, Bordeaux, France; 15Canadian Clinical Trials Group, Kingston, ON, Canada

6. A PHASE I / II STUDY OF THE SAFETY AND EFFICACY OF THE COMBINATION OF GEMCITABINE AND DOCETAXEL WTIH MORAB-004 IN METASTATIC SOFT TISSUE SARCOMA

Robin L. Jones3; Sant P. Chawla2; Steven Attia6; Patrick Schöffski4; Hans Gelderblom5; Bartosz Chmielowski7; Axel LeCesne13; Brian Van Tine8; Jonathan C. Trent9; Shreyaskumar Patel10; Andrew J. Wagner11; Rashmi Chugh12; John W. Heyburn1; Susan C. Weil1; Robert G. Maki14 1Clinical, Morphotek, Inc., Exton, PA, USA; 2Sarcoma Oncology Research Center, Santa Monica, CA, USA; 3Seattle Cancer Care Alliance, Seattle, WA, USA; 4UZ Leuven Medical Hematology Oncology, Leuven, Belgium; 5Leiden University Medical Center, Leiden, Netherlands; 6Mayo Clinic – Jacksonville, Jacksonville, FL, USA; 7Hematology/Oncology, UCLA Department of Medicine, Los Angeles, CA, USA; 8Washington University School of Medicine, St. Louis, MO, USA; 9University of Miami School of Medicine – Sylvester Comprehensive Cancer Center, Miami, FL, USA; 10MD Anderson Cancer Center, Houston, TX, USA; 11Dana-Farber Cancer Institute, Boston, MA, USA; 12Division of Hematology / Oncology, University of Michigan, Ann Arbor, MI, USA; 13Department of Medicine, Institut Gustave Roussy, Villejuif, France; 14Mount Sinai School of Medicine, New York, NY, USA

7. A PILOT FEASIBILITY STUDY OF IMMUNOTHERAPY WITH COMBINATION TRABECTEDIN AND NIVOLUMAB IN ADVANCED SOFT TISSUE SARCOMA

William W. Tseng, MD2; K. Kumar Sankhala1; Erlinda M. Gordon1; Suzan Arasheben1; Justin Daneshrad1; Sant P. Chawla1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Surgery, Section of Surgical Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

8. A NEW SYMPTOM-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SOFT TISSUE SARCOMA

Anne Rentz1; Anne Skalicky1; Sameer Ghate2; Sant P. Chawla3; Anthony P. Conley4; Victor M. Villalobos5; Jose Perez2 1Evidera, Seattle, WA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Sarcoma Oncology Center, Santa Monica, CA, USA; 4The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5University of Colorado School of Medicine, Aurora, CO, USA

Back to top


Connective Tissue Oncology (CTOS) 2015 Annual Conference in Salt Lake City, Utah

1. RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF ERIBULIN VERSUS DACARBAZINE IN PATIENTS WITH LEIOMYOSARCOMA AND ADIPOCYTIC SARCOMA: SUBGROUP ANALYSES

Sant P. Chawla, MD1; Shreyaskumar Patel2; Edwin Choy3; Viktor Gruenwald4; Peter Hohenberger5; David D’Adamo6; Ren Chen6; Giovanni Grignani7; Robin Jones8; Patrick Schöffski9; Robert G. Maki10 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; 3Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA; 4Department of Hematology, Hematosis, Oncology, and Stem Cell Transplantation, Medical School of Hannover, Hanover, Germany; 5Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, Manheim University Medical Center, Manheim, Germany; 6Eisai Inc, Woodcliff Lake, NJ, USA; 7Department of Medical Oncology, Fondazione del Piemonte per I’Oncologia IRCC, Candiolo, Italy; 8University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 9University Hospitals Leuven, Leuven, Belgium; 10Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY, USA

2. SAFETY, FEASIBILITY AND ACTIVITY OF INTRATUMORAL INJECTION OF ACTIVATED AUTOLOGOUS DENDRITIC CELLS IN SOLID TUMORS INCLUDING SOFT TISSUE SARCOMAS: A PHASE 1 CLINICAL TRIAL

Vivek Subbiah, MD1; Ravi Murthy1; David S. Hong1; Robert Prins2; Chitra Hosing1; Indreshpal Kaur1; Robert E. Brown3; Mary McGuire3; Aung Naing1; Quan D. Lin1; Anthony P. Conley1; Robert S. Benjamin1; Kamalesh Sankhala4; Sant P. Chawla4; Marnix M. Bosch5 1MD Anderson Cancer Center, Houston, TX, USA; 2ULCA, Los Angeles, CA, USA; 3Pathology, UT Health Houston, Houston, TX, USA; 4Cancer Center of California & Sarcoma Oncology Center, Santa Monica, CA, USA; 5Northwest Biotherapeutics, Bethesda, MD, USA

3. A PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF THE COMBINATION OF GEMCITABINE AND DOCETAXEL WITH ONTUXIZUMAB (MORAB-004) IN METASTATIC SOFT-TISSUE SARCOMA

Robin L. Jones3; Sant P. Chawla2; Steven Attia6; Patrick Schöffski4; Hans Gelderblom5; Bartosz Chmielowski7; Axel LeCesne13; Brian Van Tine8; Jonathan C. Trent9; Shreyaskumar Patel10; Andrew J. Wagner11; Rashmi Chugh12; John W. Heyburn1; Susan C. Weil1; Robert G. Maki14 1Clinical, Morphotek, Inc., Exton, PA, USA; 2Sarcoma Oncology Research Center, Santa Monica, CA, USA; 3Seattle Cancer Care Alliance, Seattle, WA, USA; 4UZ Leuven Medical Hematology Oncology,, Leuven, Belgium; 5Leiden University Medical Center, Leiden, Netherlands; 6Mayo Clinic – Jacksonville, Jacksonville, FL, USA; 7Hematology/ Oncology, UCLA Department of Medicine, Los Angeles, CA, USA; 8Washington University School of Medicine, St. Louis, MO, USA; 9University of Miami School of Medicine – Sylvester Comprehensive Cancer Center, Miami, FL, USA; 10MD Anderson Cancer Center, Houston, TX, USA; 11Dana-Farber Cancer Institute, Boston, MA, USA; 12Division of Hematology / Oncology, University of Michigan, Ann Arbor, MI, USA; 13Department of Medicine, Institut Gustave Roussy, Villejuif, France; 14Mount Sinai School of Medicine, New York, NY, USA

4. CONSIDERATIONS FOR LONG-TERM MAINTENANCE TREATMENT WITH DENOSUMAB FOR STABLE INOPERABLE GIANT CELL TUMOR: MAKING A CASE FOR SPACING OF DOSES AFTER INITIAL RESPONSE

Susan V. Bukata, MD1; Madhuri Sudan3; William Mendanha3; Neal S. Chawla3; Kamalesh Sankhala3; Mark A. Eckardt1; Lawrence Menendez2; Nicholas M. Bernthal1; Earl W. Brien4; Rena Emond3; Victoria S. Chua-Alcala3; Bradley A. Jabour5; Omid Jafari5; Sant P. Chawla3 1Orthopaedics, UCLA, Santa Monica, CA, USA; 2Orthopedics, USC, Los Angeles, CA, USA; 3Sarcoma Oncology, Santa Monica, CA, USA; 4Orthopedics, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 5Medical Imaging Center Southern California, Santa Monica, CA, USA

5. TRABECTIDIN: AN ACTIVE AGENT IN THE TREATMENT OF MESENCHYMAL CHONDROSARCOMA

Imran Syed1; Madhuri Sudan1; William W. Tseng2; Suzan P. Arasheben1; Bryan Leong1; Babak Aryanfar1; William Mendanha1; Neal S. Chawla1; Victoria S. Chua-Alcala1; Doris Quon1; Sant P. Chawla1; Kamalesh Sankhala1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Surgical Oncology, USC, Los Angeles, CA, USA

6. IS RADIATION WORTH THE RISK FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE ERA OF CHOP-R THERAPY?

Nicholas M. Bernthal, MD2; William Mendanha1; Kamalesh k. Sankhala1; Jeanny Hu1; Bryan Leong1; Imran Syed1; Sherif Richman3; Scott Nelson4; Lawrence Menendez5; Earl W. Brien6; Neal S. Chawla1; Mark A. Eckardt3; Jeong-Hyun Kim1; Victoria S. Chua-Alcala1; Sant P. Chawla1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Orthopaedic Surgery, UCLA, Los Angeles, CA, USA; 3UCLA, Los Angeles, CA, USA; 4Pathology, UCLA, Los Angeles, CA, USA; 5Department of Orthopaedics, USC, Los Angeles, CA, USA; 6Orthopaedic Center, Cedars Sinai, Los Angeles, CA, USA

7. A PHASE 1B/2 STUDY OF ALDOXORUBICIN + IFOSFAMIDE/MESNA IN UNTREATED SARCOMA PATIENTS

Kamalesh k. Sankhala, MD1; Neal S. Chawla1; Imran Syed1; Fritz Eilber2; Vivek Subbiah3; Victoria S. Chua-Alcala1; Kelli Sung4; Shanta Chawla4; Scott Weiland4; Daniel Levitt4; Sant P. Chawla1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Surgical Oncology, UCLA, Santa Monica, CA, USA; 3Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA; 4CytRx Corporation, Los Angeles, CA, USA

8. PHASE II STUDY OF PAZOPANIB IN PATIENTS WITH ADVANCED INTERMEDIATE OR HIGH-GRADE LIPOSARCOMA

Brian Samuels, MD1; Sant P. Chawla2; Neeta Somaiah3; Arthur Staddon4; Keith M. Skubitz5; Kevin Mulvey6; Mohammed Milhem7; Pamela Kaiser8; David Portnoy9; Dennis Priebat10; Mark Walker11; Edward Stepanski11 1Medical Oncology Associates, Post Falls, ID, USA; 2Sarcoma Oncology Center, Santa Monica, CA, USA; 3Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 4Medical Oncology, University of Pennsylvania, Philadelphia, PA, USA; 5University of Minnesota, Minneapolis, MN, USA; 6Kootenai Clinic Cancer Services, Coeur d’Alene, ID, USA; 7Medical Oncology, University of Iowa, Iowa City, IA, USA; 8Oncology Specialists, Park Ridge, IL, USA; 9West Clinic, Memphis, TN, USA; 10Medstar Washington Hospital Center, Washington,, USA; 11Vector Oncology, Memphis, TN, USA

9. SARC023: PHASE I/II TRIAL OF GANETESPIB IN COMBINATION WITH SIROLIMUS FOR REFRACTORY SARCOMAS INCLUDING MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

AeRang Kim, MD, PhD1; Scott H. Okuno2; Denise Reinke3; Vesna Milacic3; Karen Cichowski4; Thomas DeRaedt4; Perentesis John5; Sant Chawla6; Seth Steinberg7; Brigitte Widemann7 1Oncology, Childrens National Medical Center, Washington, USA; 2Mayo Clinic, Rochester, MN, USA; 3SARC, Ann Arbor, MI, USA; 4Genetics Divison, Dept of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 5Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 6Sarcoma Oncology Center, Santa Monica, CA, USA; 7National Cancer Institute, Bethesda, MD, USA

10. TRABECTEDIN (T) OR DACARBAZINE (D) FOR TREATMENT OF PATIENTS (PTS) WITH ADVANCED LEIOMYOSARCOMA (LMS) OR LIPOSARCOMA (LPS) AFTER PRIOR CHEMOTHERAPY: HISTOLOGY-SPECIFIC SUBGROUP ANALYSIS OF A RANDOMIZED PHASE-3 STUDY

George D. Demetri1; Shreyaskumar Patel2; Samuel Thomas3; Michael Livingston4; Arun Singh5; Rahul Seth6; Charles Forscher7; Ioana Hinshaw8; Gina D’Amato9; Sant P. Chawla10; Nushmia Khokhar11; George Wang11; Roland Knoblauch11; Robert G. Maki12; Margaret von Mehren13 1Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA, USA; 2The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; 3MD Anderson Cancer Center Orlando, Orlando, FL, Orlando, FL, USA; 4Blumenthal Cancer Center, Charlotte, NC, USA; 5UCLA Medical Center, Santa Monica, CA, USA; 6SUNY Upstate Medical University, Syracuse, NY, USA; 7Cedars-Sinai Medical Center, Los Angeles, CA, USA; 8Rocky Mountain Cancer Centers, Denver, CO, USA; 9Georgia Cancer Associates, Atlanta, GA, USA; 10Sarcoma Oncology Center, Santa Monica, CA, USA; 11Janssen Research & Development LLC, Raritan, NJ, USA; 12Mount Sinai School of Medicine, New York, NY, USA; 13Fox Chase Cancer Center, Philadelphia, PA, USA

11. SAFETY AND FEASIBILITY OF ALPHA PARTICLE RADIUM-223 DICLORIDE THERAPY IN HIGH RISK OSTEOSARCOMA: A PHASE 1 DOSE ESCALATION TRIAL

Vivek Subbiah, MD1; Pete Anderson2; Winston W. Huh1; VINOD RAVI1; Kenneth Hess1; Najat C. Daw1; Joanna G. Fernandez1; Neeta Somaiah1; Gregory Ravizzini1; Kamalesh Sankhala3; Sant P. Chawla3; Cindy L. Schwartz1; David S. Hong1; Eric Rohren1 1MD Anderson Cancer Center, Houston, TX, USA; 2Cleveland Clinic Foundation, Cleveland, OH, USA; 3Cancer Center of California & Sarcoma Oncology Center, Santa Monica, CA, USA

Back to top


Connective Tissue Oncology (CTOS) 2014 Annual Conference in Berlin, Germany

1. RAPID FDG-PET RESPONSE TO DENOSUMAB TREATMENT IN PATIENTS WITH GIANT CELL TUMOR OF BONE (GCTB): RESULTS FROM TWO PHASE 2 TRIALS

Keith M. Skubitz, MD1; Rodney J. Hicks2; David Thomas2; Sant P. Chawla3; Arthur Staddon4; Jacob Engellau5; Amy Feng6; Bruce A. Bach6 1Division of Hematology, Oncology, and Transplantation and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 3Sarcoma Oncology Center, Santa Monica, CA, USA; 4Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA, USA; 5Skåne Universitetssjukhus, Lund, Sweden; 6Amgen Inc., Thousand Oaks, CA, USA

2. EVALUATION OF THE CARDIAC SAFETY OF ALDOXORUBICIN, A NOVEL ALBUMIN-BINDING DOXORUBICIN PRODRUG

Kamalesh Sankhala2; Sant P. Chawla2; Victoria S. Chua2; Scott Wieland1; Daniel Levitt, MD1 1CytRx Corporation, Los Angeles, CA, USA; 2Sarcoma Oncology Center, Santa Monica, CA, USA

3. UPDATE ON PHASE 2B TRIAL OF ALDOXORUBICIN VERSUS DOXORUBICIN AS FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS

Sant P. Chawla2; Zsuszsanna Papai5; Leonid Vasylyev4; Guzel Mukhametsina3; Mamed Aliev6; Kenneth Khamly7; Scott Wieland1; Daniel Levitt, MD1 1CytRx Corporation, Los Angeles, CA, USA; 2Sarcoma Oncology Center, Santa Monica, CA, USA; 3Institute of Medical Radiology, Kharkiv, Ukraine; 4State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation; 5State Health Center, Budapest, Hungary; 6Blohkin Cancer Research Center, Moscow, Russian Federation; 7Epworth Healthcare and Clinical Research Center, Richmond Vic, QLD, Australia

Back to top


Connective Tissue Oncology (CTOS) 2013 Annual Conference in New York, New York

1. DENOSUMAB TREATMENT FOR GIANT CELL TUMOR (GCT) OF THE SPINE AND SACRUM

Sant P. Chawla1; Robert M. Henshaw2; Robert Grimer3; Keith Skubitz4; Arthur Staddon5; Peter Reichardt, MD, PhD6; Amy Feng7; Bruce A. Bach7 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Georgetown University and Medstar Washington Cancer Institute, Washington, DC, USA; 3Royal Orthopaedic Hospital, Birmingham, United Kingdom; 4University of Minnesota, Minneapolis, MN, USA; 5Pennsylvania Oncology Hematology Associates, Philadelphia, PA, USA; 6HELIOS Klinikum Berlin-Buch, Berlin, Germany; 7Amgen, Inc., Thousand Oaks, CA, USA

2. PART 1 OF A MULTICENTER, TWO-PART, PHASE II STUDY OF THE SAFETY AND EFFICACY OF THE COMBINATION OF GEMCITABINE AND DOCETAXEL WITH MORAB-004 IN METASTATIC SOFT TISSUE SARCOMA

Robin L. Jones1; Donald A. Berry2; Sant P. Chawla3; Bartosz Chmeilowski4; Andrew Wagner5; Patel Shreyaskumar6; Anthony P. Conley6; Damon Reed7; Chu R. Shin, MD8; Susan C. Weil8; John Heyburn9; Lindsey Schulert9; Ann-Marie Hulstine9; Robert G. Maki, MD, PhD10 1Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Berry Consultants, LLC, Austin, TX, USA; 3Sarcoma Oncology Center, Santa Monica, CA, USA; 4Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA; 5Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 6Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA; 7Sarcoma Program, Moffitt Cancer Center, Tampa, FL, USA; 8Clinical Development, Morphotek, Inc., Exton, PA, USA; 9Clinical Operations, Morphotek, Inc., Exton, PA, USA; 10Departments of Medicine, Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA

3. A RANDOMIZED PHASE 2B STUDY COMPARING TREATMENT WITH ALDOXORUBICIN VERSUS DOXORUBICIN FIRST LINE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS

Kamalesh Sankhala1; Zsuzsanna Papai4; Sant P. Chawla3; Guzel Mukhametsina7; Mamed Aliev8; Leonid Vasylyev6; Kennith Khamly10; Rajnish Nagarkar9; Cornelia Toganel5; Hillary Trent2; Scott Wieland2; Daniel Levitt, MD, Ph.D2 1Institute for Drug Development, University of Texas Medical School, San Anonio, TX, USA; 2CytRx Corporation, Los Angeles, CA, USA; 3Sarcoma Oncology Center, Santa Monica, CA, USA; 4Oncology Department, State Health Center, Budapest, Hungary; 5Clinical County Emergency Hospital, Baia MAre, Romania; 6Chemotherapy Department, Institute of Medical Radiology, Kharkiv, Ukraine; 7State Healthcare Institution, Republican Clinical Oncological Center of the Republic of Tatarstan, Kazan, Russian Federation; 8Bhlokin Cancer Research Center, Moscow, Russian Federation; 9Curie Curie Manavata Cancer Centre, Mumbai, India; 10Epworth HealthCare Clinical Trials and Research Centre, Richmond, VIC, Australia

4. RESULTS FROM A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY OF THE HEDGEHOG (HH) PATHWAY ANTAGONIST IPI-926 IN PATIENTS (PTS) WITH ADVANCED CHONDROSARCOMA (CS)

Andrew Wagner, MD, PhD1; Peter Hohenberger2; Scott Okuno3; Mikael Eriksson4; Patel Shreyaskumar5; Stefano Ferrari, MD6; Paolo G. Casali7; Sant P. Chawla8; Molly Woehr9; Robert Ross9; Jessica O’Keeffe9; Amy Hillock9; George Demetri1; Peter Reichardt, MD, PhD10 1DFCI, Boston, MA, USA; 2Universitätsmedizin Mannheim, Mannheim, Germany; 3Mayo Clinic, Rochester, MN, USA; 4Skånes Universitetssjukhus i Lund, Lund, Sweden; 5M.D. Anderson Cancer Center, Houston, TX, USA; 6IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; 7Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 8Sarcoma Oncology Center, Santa Monica, CA, USA; 9Infinity Pharmaceuticals, Inc., Cambridge, MA, USA; 10Helios Klinikum Bad Sarrow, Bad Saarow, Germany

5. EXPLORATORY ANALYSIS FOR THE EVALUATION OF RESPONSE (RECIST VS. CHOI CRITERIA) IN THE PHASE III TRIAL OF TRABECTEDIN VS. DOXORUBICIN-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PATIENTS WITH TRANSLOCATION-RELATED SARCOMA (TRS)

Jean-Yves Blay1; Michael Leahy2; Binh Bui3; Patel Shreyaskumar4; Peter Hohenberger5; Armando Santoro6; Arthur P. Staddon7; Nicolas Penel, MD PhD8; Sophie Piperno-Neumann, MD9; Pilar Lardelli10; Javier Gómez10; José Alberto Nadal Martínez10; Iratxe Pérez Viejo10; Bernardo De Miguel Lillo10; Sant P. Chawla11 1Centre Léon Bérard, Lyon, France; 2The Christie NHS Foundation Trust, Manchester, United Kingdom; 3Institut Bergonie, Bordeaux, France; 4University of Texas; MD Anderson Cancer Center, Houston, TX, USA; 5Universitätsklinikum Mannheim, Mannheim, Germany; 6Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy; 7Pennsylvania Hospital, Philadelphia, PA, USA; 8Centre Oscar Lambret, Lille, France; 9Institut Curie, Paris, France; 10PharmaMar, Madrid, Spain; 11Sarcoma Oncology Center, Santa Monica, CA, USA

6. RANDOMIZED PHASE III TRIAL OF TRABECTEDIN (T) VERSUS DOXORUBICINBASED CHEMOTHERAPY (DXCT) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH TRANSLOCATIONRELATED SARCOMA (TRS)

Sant P. Chawla1; Andrew E. Hendifar1; Michael Leahy2; Antoine Italiano3; Patel Shreyaskumar4; Peter Hohenberger5; Armando Santoro6; Arthur P. Staddon7; Nicolas Penel, MD PhD8; Sophie Piperno-Neumann, MD9; Pilar Lardelli10; Antonio Nieto10; Carmen Kahatt10; Jean Yves Blay11 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; 3Institut Bergonié, Bordeaux, France; 4The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Universitätsklinikum Mannheim, Mannheim, Germany; 6Humanitas Cancer Center, Rozzano, Italy; 7Pennsylvania Hospital, Philadelphia, PA, USA; 8Centre Oscar Lambert, Lille, France; 9Institut Curie, Paris, France; 10PharmaMar, Colmenar Viejo, Spain; 11University Claude Bernard Lyon I, Centre Léon Bérard, Lyon, France

7. RANDOMIZED PHASE 3, MULTICENTER, OPEN-LABEL STUDY COMPARING TH-302 IN COMBINATION WITH DOXORUBICIN VS. DOXORUBICIN ALONE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA

William D. Tap1; Kristen N. Ganjoo, MD2; Brian A. Van Tine3; Zsuzsanna Papai4; Sant P. Chawla5; Scott Schuetze6; Lee D. Cranmer7; Damon Reed8; Thierry Alcindor9; Massimo Aglietta10; Antonio Lopez-Pousa11; Piotr Rutkowski, MD, PhD12; Daniela Katz13; Torsten Kessler14; Patrick Schoffski15 1Sarcoma Oncology, Memorial Sloan-Kettering Cancer Center, NY, NY, USA; 2Stanford University, Palo Alto, CA, USA; 3Washington University, St. Louis, MO, USA; 4State Health Center Oncology Department, Budapest, Hungary; 5Sarcoma Oncology Center, Santa Monica, CA, USA; 6University of Michigan, Ann Arbor, MI, USA; 7University of Arizona Cancer Center, Tuscon, AZ, USA; 8H. Lee Moffitt Cancer Canter & Research Institute, Tampa, FL, USA; 9McGill University Health Centre, Montreal, QC, Canada; 10Medical Oncology, IRCC Institute for Cancer Research and Treatment, Candiolo, Italy; 11Hospital De Sant Pau, Barcelona, Spain; 12Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 13Sharett Institute of Onc, Hadassa-Hebrew University Medical Center, Jerusalem, Israel; 14University of Muenster Hospital, Muenster, Germany; 15Universitaire Ziekenhuis Gasthuisberg, Leuven, Belgium

8. ROLE OF DENOSUMAB IN GIANT CELL TUMOR OF SPINE AND SACRUM: A SINGLE CENTER STUDY

Monish Sodhi, M.D.1; Susan Bukata2; Doris V. Quon1; Vivek Narasimhan1; Andre Saralou1; Victoria Chua1; Ashok Peter1; Timor Pogodin1; Kamalesh Sankhala1; Sant P. Chawla1 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2UCLA, Santa Monica, CA, USA

Back to top


Connective Tissue Oncology (CTOS) 2012 Annual Conference held in Prague, Czech Republic.

Our presentations:

1) PHASE 3, PLACEBO-CONTROLLED TRIAL (SUCCEED) EVALUATING RIDAFOROLIMUS AS MAINTENANCE THERAPY IN ADVANCED SARCOMA PATIENTS FOLLOWING CLINICAL BENEFIT FROM PRIOR STANDARD CYTOTOXIC CHEMOTHERAPY: SUBGROUP ANALYSIS OF PATIENTS AFTER SECOND- AND THIRD-LINE THERAPY

Sant Chawla1; Peter Reichardt2; Isabelle Ray-Coquard3; Axel Le Cesne4; Arthur P. Staddon5; Mohammed M. Milhem6; Nicolas Penel7; B. Bui Nguyen8; Yang Song9; Scot Ebbinghaus10; Frank G. Haluska11; Pierre F. Dodion12; Jean-Yves Blay3; George D. Demetri13

1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Hematology, Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany; 3Medicine, Centre Léon Bérard Cancer Center, Lyon, France;4Medical Oncology, Institut Gustave Roussy, Villejuif, France; 5Oncology Hematology, Joan Karnell Cancer Center-Pennsylvania Hospital, Philadelphia, PA, USA; 6Internal Medicine, University of Iowa, Iowa City, IA, USA; 7General Oncology, Centre Oscar Lambert, Lille, France; 8Medical Oncology, Institut Bergonié, Bordeaux, France; 9Clinical Biostatistics Oncology, Merck, Whitehouse Station, NJ, USA; 10Clinical Research/Oncology, Merck, Whitehouse Station, NJ, USA; 11Clinical Research and Development, ARIAD, Cambridge, MA, USA;12Oncology,

2) A PHASE II TRIAL OF NOVEL ANTHRACYCLINE AMRUBICIN IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA

Launce G. Gouw, MD, PhD1; R Lor Randall2; Sant Chawla3, Sunil Sharma1 1Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA; 2Orthopaedics, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA; 3Sarcoma Oncology Center, Santa Monica, CA, USA

3) TH-302 MAINTENANCE FOLLOWING TH-302 PLUS DOXORUBICIN INDUCTION: THE RESULTS OF A PHASE 2 STUDY OF TH-302 IN COMBINATION WITH DOXORUBICIN IN SOFT TISSUE SARCOMA

Kristen N. Ganjoo1; Lee Cranmer2; Brian Van Tine3; Damon R. Reed4; Scott H. Okuno5; James E. Butrynski6; Douglas Adkins3; Andrew Hendifar7; Esther D. Chu8; Stew Kroll8; Sant P. Chawla7
1Oncology, Stanford University Medical Center, Stanford, CA, USA; 2Oncology, Arizona Cancer Center, Tucson, AZ, USA; 3Oncology, Washington University, St. Louis, MO, USA; 4Oncology, Moffitt Cancer Center, Tampa, FL, USA; 5Oncology, Mayo Clinic Rochester, Rochester, MN, USA; 6Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 7Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 8Clinical Operations, Threshold Pharmaceuticals, South San Francisco, CA, USA

4) ALDOXORUBICIN (INNO-206) IS AN ACTIVE DRUG FOR THE TREATMENT OF RELAPSED OR REFRACTORY SOFT TISSUE SARCOMAS

Sant Chawla2; Victoria Chua2; Andrew Hendifar2; Lita Fernandez2; Scott Wieland1; Vivek Narasimhan2; Harsha Rajashekharaiah2; Kamalesh Sankhala3; Kristen Ganjoo4; Daniel Levitt1 1CytRx Corporation, Los Angeles, CA, USA; 2Medical Oncology, Sarcoma Cancer Center, Los Angeles, CA, USA; 3Medical Oncology, University of Texas San ANtonio Medical Center, San Antonio, TX, USA;4Medical Oncology, Stanford University Medical Center, Stanford, CA, USA

5) LOW DOSE GEMCITABINE, DOXORUBICIN, AND DOCETAXEL COMBINATION IN PATIENTS WITH ADVANCED, UNRESECTABLE AND/OR METASTATIC SARCOMA WHO HAD FAILED PRIOR CHEMOTHERAPY, AN UPDATED ANALYSIS

Sant P. Chawla; Vivek Narasimhan; Andrew E. Hendifar; Victoria Chua; Doris Quon; Lita Fernandez; Harsha Rajashekaraiah; David Shin; Sarcoma Oncology Center, Santa Monica, CA, USA

6) 14 DAY CONTINUOUS INFUSION OF HIGH-DOSE IFOSFAMIDE IN ADOLESCENT AND ADULT SARCOMA PATIENTS, AN UPDATED ANALYSIS

Sant Chawla1; Harsha Rajashekharaiah1; Andrew Hendifar1; Victoria Chua1; Doris Quon1; Lita Fernandez1; Kristen Ganjoo3; Kamalesh Sankhala1; Vivek Narasimhan1; David Shin21Sarcoma Oncology Center, Santa Monica, CA, USA; 2UCLA, Santa Monica, CA, USA; 3STANFORD, Palo Alto, CA, USA

Back to top


Connective Tissue Oncology (CTOS) 2011 Annual Conference

This years meeting, held in Chicago, Illinois, was the first combined Musculoskeletal Tumor Society and Connective Tissue Oncology meeting in their prestigious histories.

The conference was excellent and new therapies in the treatment of Ewing’s sarcoma, osteosarcoma, and soft tissue sarcom a were presented. Their was an excellent talk by Dempsey Springfield who honored Frederick Eilber and Jeffery Eckardt for heir contributions to the care of sarcoma patients.

Our center presented several papers describing new advances in the care of sarcoma patients.
1. A PHASE 2 STUDY OF TH-302 IN COMBINATION WITH DOXORUBICIN IN ADVANCED SOFT TISSUE SARCOMA

Sant P. Chawla1, Kristin N. Ganjoo2, Douglas Adkins3, Damon Reed4, Scott H. Okuno5, James E. Butrynski6, Daniel Rushing7, Brain Van Tine3, Esther D. Chu8, Stew Kroll8, Lee Cranmer9

2. 14 DAY CONTINUOUS INFUSION HIGH-DOSE IFOSFAMIDE IN ADOLESCENT AND ADULT SARCOMA PATIENTS Andrew Hendifar, Shelly Chawla, Sandeep Nagre, Vicky Chua, Lita Fernandez, Bartosz Chmielowski, James Hu, and Sant Chawla

3. Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): Interim Results From a Phase 2 study

Sant Chawla,1 Jean-Yves Blay,2 Javier Martin Broto,3 Edwin Choy,4 Martin Dominkus,5 Jacob Engellau,6 Robert Grimer,7 Robert Henshaw,8 Emanuela Palmerini,9 Peter Reichardt,10 Piotr Rutkowski,11 Keith Skubitz,12 David Thomas,13 Yufan Zhao,14 Yi Qian,14 Ira Jacobs14

4.Exploratory Analysis of Potential Predictive Markers to Identify Sensitive/Responder Sarcoma Patients with Ridaforolimus in the Phase 3 Randomized Placebo-controlled Trial (SUCCEED)

G. D. Demetri, S. P. Chawla, I. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, R. F. Riedel, B. Bui Nguyen, L. D. Cranmer, P. Reichardt, E. Bompas, Y. Song, R. M. Lee, J. E. Eid, J. Loewy, F. G. Haluska, P. F. Dodion, J. Y. Blay

Download the presentations: Denosumab_for_Giant_Cell (1)    Ifosfamide_for_Sarcoma    Threshold_for_Sarcoma    Ridaforolimus_for_Sarcoma

Back to top


Connective Tissue Oncology (CTOS) 2010 Annual Conference

CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues. The goal of the society is to advance the care of patients with connective tissue tumors and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research.

In 2010, the Sarcoma Oncology Center presented several new therapies for the treatment of sarcoma:

1. Efficacy and Safety of Conatumumab Plus AMG 479 in Patients With Advanced Sarcoma. S Chawla,1 AC Lockhart,2 N Azad,3 E Elez,4 F Galimi,5 N Baker,6 YJ Hei,5 H Kindler7
AMG 479 is an investigational, fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF1R). Binds to IGF1R and prevents binding of its ligands, IGF-1 and IGF-2. Conatumumab is an investigational, fully human monoclonal antibody against human death receptor 5 (DR5). It binds to DR5, activates caspases, and induces apoptosis. Prolonged stable disease was noted in 3 patients and it was very well tolerated.

2. A Phase 2 Study of Nanoparticle Albumin-Bound (NAB) Paclitaxel in the Treatment of of Patients with Unresectable or Metastaic Sarcoma. James E. Butrynski1, Rangarajan Nadadur2, Thierry Jahan3, Victoria Chua4, Claire Bautista Lazaro4, Sant Chawla4
nab-Paclitaxel is a novel biologically interactive, albumin-bound Paclitaxel combining a protein with a chemotherapeutic agent in a particle form. In principle, this composition provides a novel approach of increasing intra-tumoral concentration of the drug by a receptor-mediated transport process allowing transcytosis across the endothelial cell wall.

3. Denosumab in Giant Cell Tumor of Bone: Interim Results From a Phase 2 Study. Sant Chawla1, Angela Cioffi2, Judith R. Kroep3; Alex Powell4, Peter Reichardt5, Scott M. Schuetze6, Silvia Stacchiotti7, Arthur Staddon8, Yi Qian9, Kay Noonan9, Ira Jacobs9
This interim analysis reports: 1. Safety results for all patients who received = 1 dose of denosumab as of the 6-month data cut-off date 2. Efficacy results for patients who had the opportunity to receive denosumab treatment for = 6 monthsAfter 6 months, 47 patients (96%) were free of disease progression based on subjective assessment of disease status

4.Threshold + Adriamycin for Soft Tissue Sarcomas
“We are very pleased to have achieved a response rate of 33% in a meaningful number of patients which compares favorably with historic, albeit controlled data. The durability of response is also quite promising,” said John Curd, M.D., Threshold’s chief medical officer. “If confirmed in a controlled trial, the potential benefit to sarcoma patients of TH-302 plus doxorubicin would be greatsignificantly better than the current standard of doxorubicin alone for these patients who are in serious need of better treatment options.”

Download the presentations: Abraxane CTOS 2011    amg 479    Denosumab CTOS 2011

Chemotherapy Symposium 2014

The Sarcoma Oncology Center is proud to present Dr. Sant Chawla’s presentation at the Chemotherapy Symposium – “Drug Conjugates Bind Covalently to Albumin: A New Approach.”

Dr. Chawla presented on Albmin, finding the following conclusions:

  • Aldoxorubicin significantly increases PFS, PFS at 6 months and ORR compared to doxorubicin therapy for first line STS.
  • Grade 3 or 4 neutropenia, mucositis and nausea/vomiting are higher in aldoxorubicin-treated patients but are not treatment limiting.
  • The aldoxorubicin patients received more than 5 times the cumulative amount of doxorubicin in this study than the doxorubicin patients without any evidence of clinically relevant decreased LVEF, and in more instances an increase in LVEF, either by MUGA or echocardiogram.
  • A phase 3 pivotal trial under a SPA is ongoing for relapsed/refractory STS.
  • Aldoxorubicin has the potential to replace doxorubicin in the chemotherapy armamentarium to treat both adult and pediatric cancers.
  • Download the presentation: Chemo14Chawla

Back to top